Loading, Please Wait...
-Teleconference Scheduled for February 27, 2019, at 5:00 p.m. ET-
-Company to Host Research and Development Day on February 26, 2019 in New York City-
SOUTH SAN FRANCISCO, Calif., Feb. 14, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platform, plans to report full-year 2018 financial results on Wednesday, February 27, 2019, after the close of U.S. markets. Following the announcement, the company will host a conference call beginning at 5:00 p.m. ET to discuss its results.
Participants may access the live audio webcast of the teleconference from the “Investors & News” section of CytomX’s website at http://ir.cytomx.com/ . Please access the website 15 minutes prior to the start of the call to download and install any necessary audio software.
|Audio Conference Call:|
|U.S. Dial-in Number:||(877) 809-6037|
|International Dial-in Number:||(615) 247-0221|
An archived webcast replay will be available on the Company's website from February 27, 2019, until March 6, 2019.
CytomX Therapeutics’ 2019 Research and Development Day
CytomX plans to host a Research and Development Day on February 26, 2019 from 8:00 a.m. – 11:30 a.m. ET in New York City.
The event will be webcast live under the “Investors & News” section of CytomX’s website at http://ir.cytomx.com/events-and-presentations. Please connect to the webcast several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary. An archived webcast replay will be available on the Company's website for 90 days following the event.
Institutional investors and equity analysts seeking information on or registration for the live event in New York City please contact Chris Keenan at ckeenan@CytomX.com.
About CytomX Therapeutics
CytomX Therapeutics is a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platform. Probody therapeutics are designed to exploit unique conditions of the tumor microenvironment to more effectively localize antibody binding and activity while limiting activity in healthy tissues. CytomX and its partners have four programs in the clinic. The Company’s pipeline includes cancer immunotherapies against clinically-validated targets, including a PD-L1-targeting Probody therapeutic wholly owned by CytomX (CX-072), a PD-1-targeting Probody therapeutic wholly owned by CytomX (CX-188) and a CTLA-4-targeting Probody therapeutic partnered with Bristol Myers Squibb (BMS-986249). The pipeline also includes first-in-class Probody drug conjugates against highly attractive targets including a CD166-targeting Probody drug conjugate wholly owned by CytomX (CX-2009), and a CD71-targeting Probody drug conjugate partnered with AbbVie (CX-2029). CD166 and CD71 are among cancer targets that are considered to be inaccessible to conventional antibody drug conjugates due to their presence on many healthy tissues. In addition to its wholly owned programs, CytomX has strategic collaborations with AbbVie, Amgen, Bristol-Myers Squibb Company and ImmunoGen, Inc. For more information, visit www.cytomx.com.
Investors and Media:
VP, Investor Relations and Corporate Communications